Steve Myatt, the newly-appointed chief executive of Macomics By Kristy Dorsey Macomics, a drug discovery spin-out from the University of Edinburgh, has raised a further £4.2 million in funding and announced three new senior appointments as it progresses its work in the field of tackling cancer tumours. The deal was led by transatlantic scientific investors Epidarex Capital following initial seed funding of £3.2m from Epidarex and the Scottish Investment Bank in the middle of last year. Edinburgh-based investment fund Caribou Property has joined as a new investor in this latest round. Co-founded in 2019 by the university’s Jeffrey Pollard and Luca Cassetta, Macomics is focused on the role of macrophages in increasing the body’s immune defence against tumours. It has R&D and office facilities in Edinburgh and Cambridge.